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Bioinspired silica as drug delivery systems and their
biocompatibility†
Christopher R. Steven,‡ab Grahame A. Busby,‡ac Craig Mather,a Balal Tariq,ac
Maria Lucia Briuglia,d Dimitrios A. Lamprou,d Andrew J. Urquhart,§*dM. Helen Grant*c
and Siddharth V. Patwardhan*a
Silica nanoparticles have been shown to have great potential as drug delivery systems (DDS), however, their
fabrication often involves harsh chemicals and energy intensive laborious methods. This work details the
employment of a bioinspired “green” method for the controlled synthesis of silica, use of the products to
entrap and release drug molecules and their cytotoxicity in order to develop novel DDS. Bioinspired silica
synthesis occurs at pH 7, room temperature and in less than 5 minutes, resulting in a rapid, cheaper and
greener route. Drugs were loaded into silica during the silica formation, thus allowing a one step and
one pot method for simultaneous silica synthesis and drug loading. We established that the drug release
proﬁle can be modulated by synthetic parameters, which can allow design of tailored DDS. A systematic
investigation using a two level factorial design was adopted in order to identify the key synthetic
parameters and quantify their eﬀects on silica formation, drug loading and drug release. The observation
that these new DDS are considerably less cytotoxic than their current counterparts, and exhibit
additional beneﬁts such as green synthesis and ease of functionalization, strengthens the argument for
their future use in DDS and other biomedical applications.
1. Introduction
The nanotechnology market is expanding rapidly,1 however,
understanding of the toxicity of nanostructured materials has
started to emerge only recently due to their biomedical use such
as in drug delivery systems (DDS). Nanomaterial based
biomedical devices, such as DDS, are of growing importance in
eﬀective clinical treatment2 and cover a wide range of chemis-
tries.3 Despite the extensive eﬀorts on nanomaterial based DDS
over decades, a relatively small number have been approved and
are under the clinical trials stage for clinical use.4 Silica based
nanomaterials as DDS have attracted considerable attention due
to their ability to control drug loading, porosity and surface
chemistry (through functionalisation).5 Silica has been approved
by the US Food and Drug Administration as “Generally Recog-
nised As Safe” and by the EU for its use in cosmetics and food
additives.4,6Furthermore, syntheses of a rangeof distinct types of
silica are well-established.4,6–8 Finally, silica has excellent
biodegradation properties9 and dissolved silica has been sug-
gested as benecial to bones.10
Most of the studies use amorphous xerogels, fumed silica
nanoparticles or mesoporous silica such as MCM-41 or SBA-15.
In particular mesoporous silica nanoparticles (MSN) have a
relatively large pore volume, a unique mesoporous structure
and provide a high surface area for drug molecule adsorption,
as a result they have been of wide interest in DDS.4,11 For
example, MSN loaded with the anticancer drug doxorubicin
(DOX) was administered to mice and caused a signicant
reduction in mean tumour weight, beyond the eﬀect observed
with free DOX treatment.12,13 However, since the drug was
loaded on silica by physisorption post-synthesis, it limits any
control of sustained release parameters. Alternatively, post-
synthesis functionalization can be used to modulate the drug
release but this severely has impact on other aspects such as the
pore volume of the silica used14 and increased complexity in the
synthesis of such DDS. Typical strategies to oﬀer controlled
release, and, in some cases, stimuli responsive release, involve
capping of MSN pores. Song et al. used mesoporous silica (SBA-
15) which can be functionalized by amine surface groups prior
to loading of bovine serum albumin (BSA) into the silica
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followed by encapsulation in polyacrylic acid.15 Another study
used MCM-41 to load vancomycin and adenosine triphosphate
(ATP) and capped the pores with toxic cadmium sulphide (CdS)
to trap drugs thus avoiding unwanted drug release.16 Although
the strategies discussed above can produce eﬀective DDS, they
typically involve two to four steps in the fabrication of DDS:
silica synthesis, surface functionalisation of silica, drug loading
and capping of the pores. Recently, a one-step synthesis of silica
gels for in situ drug encapsulation was investigated where
propanolol and persantin were dissolved with the silica
precursor and the fabrication required 24 hours and acidic pH
(0.5–5.5).17
The current use of silica in this way has some limitations,
however. Silica, in particular, MSN tend to be synthesised under
harsh conditions (elevated temperature, high pressure, strongly
alkaline or acidic solutions), with multistep preparations taking
several days. Furthermore, they require either a high tempera-
ture (600 C) calcination step or template extraction using
concentrated acid prior to loading a drug molecule resulting in
additional cost, time and complexity in fabricating DDS.18 With
limited exibility, the synthesis of the mesoporous silica
remains diﬃcult to manipulate, and control over the drug
release rate is diﬃcult to achieve. The release of any hydrophilic
drug appears very rapid but controlling this release seems more
of an issue. Burst release from the silica will confer no advan-
tage over free drug. For example, one study showed that the
control of the pore size to slow drug release19 also reduced the
drug loading by leaving only a tortuous path into the matrix for
the drug molecules.20 Clearly, the fabrication of silica DDS is an
area warranting further investigation where milder and simpler
routes can be established for DDS preparation, while also
oﬀering control over physical properties of DDS which in turn
controls the drug loading and release. Furthermore, confusion
regarding their safe use is widespread, especially because the
interactions at the nano-bio interface are unknown.21 For
example, MSN have been shown to be toxic, especially above 25
mg ml1 concentrations for submicron sized particles.4,22
Although the risk of signicant reduction in cell viability in the
presence of MSN can be minimised by functionalisation, this is
known to lead to complex cell responses.23 It is therefore of
utmost importance to carefully and thoroughly investigate the
biocompatibility and any toxic eﬀects of nanomaterials that are
intended for use in biomedical applications. Taking all these
factors into consideration, the potential negative impact can
outweigh the benets MSN can oﬀer.
In recent years, there has been signicant growth in the
research on biological and biologically inspired silica forma-
tion.24–27 For example, researchers have probed mechanisms of
biosilica formation and it has become apparent that certain
biomolecules (typically rich in amines) play a crucial role in
biosilica deposition, where the chemistry and architecture of
these biomolecules are important. Learning from nature, in
vitro experiments on silica formation have developed bio-
inspired green routes to nanostructured and porous silica by
utilising a wide variety of “additives” (analogues of biomole-
cules).24,28 Green nanosilica (GN) synthesis is far safer, routinely
performed on bench-top at room temperature in water and
takes about 5 minutes. A large number of reports have recently
discussed the advantages of employing this bioinspired route in
the synthesis of silica (extensively reviewed in ref. 24).
Furthermore, control over properties of GN, including particle
size and porosity, is possible.29 This control in green synthesis
can be readily achieved by the ‘correct’ choice of an additive and
synthesis conditions. It is clear that the utilisation of this
approach for the fabrication of silica nanoparticles as DDS has
the potential to oﬀer a one step, “green” synthesis in contrast to
the time, energy and material intensive methods which are
detailed above for traditional materials.24,28–30
The bioinspired silica synthesis has been employed to
support or encapsulate quantum dots,31 catalysts,32 enzymes33–35
and uorescent molecules,36,37 however, there appears to be only
one literature report on drug delivery.38 This report immobilised
a dual-function protein which was able to both precipitate silica
and act as an anti-cancer agent. The release of protein from the
silica was thought to be achieved by the hydrolysis of the silica
giving a sustained release. The one step fabrication relied upon
the dual functionality of the protein used, however, this
approachmay not be applicable to a broad set of drugmolecules
and thus further investigations are warranted.
In this work, we aim to further explore the possibility of
using GN for DDS by systematically and extensively focusing on
the synthesis of the DDS with a view to understand their
fabrication, drug loading and drug release. Since the method
presented here achieves drug loading while silica formation
occurs, controlling silica chemistry in the presence of the drug
is of great importance in order to keep both the drug and silica
minimally aﬀected, while simultaneously allowing the drug to
be released when desired. In this report we aim to (1) establish
the use of GN as DDS and understand the drug release mech-
anisms using a model drug-like compound (Sections 3.1 and
3.2); (2) use design of experiments to identify key synthetic
conditions and quantify their eﬀects on DDS fabrication and
drug release (Section 3.3); and (3) apply GN DDS for loading and
releasing several therapeutically useful drugs (Section 3.4). We
note that the toxicity of bioinspired silica has not been previ-
ously reported despite their proven potential in drug delivery,
biocatalysis, carbon capture and environmental decontamina-
tion.39–42 Therefore, we also aim to (4) investigate cytotoxicity of
bioinspired silica (Section 3.5). Drug delivery and biocompati-
bility in biological systems form part of future investigations.
2. Experimental
2.1 Chemical reagents
The following chemical reagents were used and are listed along
with their indicated purity, where available, and supplier.
Sodium metasilicate (Na2SiO3$5H2O, $95%, Sigma Aldrich),
tetraethylorthosilicate (TEOS, Sigma-Aldrich), 3-aminopropyl-
trimethoxysilane (APTMOS, Sigma-Aldrich), 2-(4-chlor-
osulphonylphenyl)ethyltrimethoxysilane (CSTMOS, Fluo-
rochem), cetyltrimethylammonium bromide (CTAB, Sigma-
Aldrich) calcein (SigmaAldrich), Nile red (technical grade, Sigma
Aldrich), diethylenetetramine DETA (99%, Sigma Aldrich), trie-
thylenepentamine TEPA (technical grade, Sigma Aldrich),
This journal is © The Royal Society of Chemistry 2014 J. Mater. Chem. B, 2014, 2, 5028–5042 | 5029
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pentaethylenehexamine PEHA (technical grade, Sigma Aldrich),
polyallylamine hydrochloride PAH (15 kDa, $95%, Sigma
Aldrich), 1MHCl (0.950–1.050M, SigmaAldrich), andphosphate
buﬀered saline (PBS) tablets (137 mM NaCl, 2.7 mM KCl and 10
mM phosphate buﬀer solution, pH 7.4 at 25 C, Sigma Aldrich).
Pindolol, atenolol and ibuprofen were purchased from Sigma
Aldrich. Pindolol is a nonselective beta blocker with partial beta-
adrenergic receptor agonist activity, log P¼ 1.75, pKa¼ 9.25, l¼
210 nm, water solubility ¼ 7.8 mg ml1. Atenolol is a selective
beta1 receptor antagonist, which is used for the treatment in
cardiovascular disease, log P¼ 0.16, pKa¼ 9.6, l¼ 230 nm,water
solubility ¼ 13.5 mg ml1. Ibuprofen (sodium salt) is an NSAID
(non-steroidal anti-inammatory drug) that is commonly used
for the relief of symptoms of arthritis, fever, primary dysmen-
orrhea, and as an analgesic, log P ¼ 3.9, pKa ¼ 4.9, l ¼ 214 nm,
water solubility ¼ 100 mg ml1. The chemical structures of the
additives used in silica formation and the drug/drug-like mole-
cules are shown in Scheme 1.
2.2 Silica synthesis
2.2.1 Sto¨ber silica nanoparticles. 42.72 ml ammonia (1 M)
was added to 158.2 ml of 95% ethanol in a 250 ml glass Erlen-
meyer ask. In another ask 44.61 ml tetraethyl silicate (TEOS)
was dilutedwith 153.2ml of 95% ethanol. Theaskswere heated
at 50 C for 80 min in a water bath. The two solutions were then
mixed and allowed to mature for 2 days under constant slow
stirring. The silica particles were then separated from the
resulting solution by centrifugation. The particles were washed
in ethanol before being resuspended by sonication in 1 M HCl
overnight. The following day the particles were washed again via
repeated centrifugation cycles before being dispersed in a little
ethanol and allowed to dry for several hours in an oven (80 C).
2.2.2 Functionalised mesoporous silica nanoparticles
(MSN).MSN are typically functionalised by using graing or co-
condensation.43 In graing, MSN are modied post-synthesis,
while in co-condensation, MSN are functionalised during
synthesis. Due to the possibilities of a shorter preparation time
and homogeneous distribution of functional groups achieved
by the co-condensation method, it was preferred here. Using
this method, acid and base functionalised organosilanes were
condensed together with a silica precursor to produce func-
tionalised mesoporous silica nanoparticles as described in the
literature.44,45
A co-condensation reaction was used in the synthesis of
basic aminopropyl or sulfonic acid functionalised MSN
producing APMSN or SAMSN respectively. TEOS was used as a
silica precursor. Silane coupling agents CSTMOS and APTMOS
were used to produce SAMSN and APMSN respectively. The
surfactant used was CTAB. The rst stage of this method is to
heat 480 ml of DI water to 80 C followed by the addition of
CTAB and 2 M NaOH (7 ml of water, 14 mmol of NaOH), and the
mixture was stirred constantly at 80 C. Aer 30 minutes, 10 ml
TEOS (51.4 mmol) was added to the solution followed by
immediate addition of either 1 mmol of CSTMOS (0.237 ml) for
SAMSN synthesis, or 1 mmol of APTMOS (0.18 ml) for APMSN
synthesis. The solution remained at 80 C and was vigorously
stirred for 2 hours. To separate the synthesised material, the
reactionmixture was poured into the lter funnel whilst still hot
and was washed with copious amounts of methanol. The solid
obtained on the lter paper was dried in a vacuum oven for
approximately 8 hours at 80 C.
Aer vacuum drying, the surfactant CTAB was required to be
removed by methanol extraction. To pre-heated 100 ml meth-
anol (60 C) 1 g of solid MSN was added with vigorous stirring. 1
Scheme 1 Chemical structures of the additives used in silica formation (a and b). For ethyleneamines, n ¼ 2 is DETA, n ¼ 4 is TEPA and n ¼ 5 is
PEHA. Chemical structures of (c) calcein, (d) nile red, (e) pindolol, (f) atenolol and (g) ibuprofen.
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ml concentrated hydrochloric acid was then added and the
solution was vigorously stirred at 60 C for 6 hours. The solid
with the surfactant removed was obtained through hot ltration
and again was washed with a copious amount of methanol. The
solid collected was then vacuum dried for approximately 8
hours at 90 C. The complete removal of CTAB was conrmed by
FTIR analysis.
2.2.3 Bioinspired green nanosilica (GN). A desired amine
additive (e.g. pentaethylenehexamine PEHA) was dissolved in
distilled H2O and mixed with sodium metasilicate and a pre-
determined amount of 1 M HCl was added quickly to reach pH
7. The concentrations of sodium metasilicate and amine in the
nal volume were 30 mM. The silica particles began to form in
seconds. The mixture was allowed to react for 5 minutes (unless
otherwise stated) before being centrifuged at 8000 rpm and
washed three times. The wet samples were dried at 85 C for 5
hours. The samples were labelled as “amine”–GN (e.g. PEHA–
GN). For samples containing drug, silicate was dissolved in
water and to this a solution of drug molecule was added. A
solution of the rate enhancing amine additive was then added
and the pH was adjusted to 7. Samples were washed and
collected as above. The supernatants aer each centrifugation
were used to quantify the amount of drug loaded onto silica by
using UV-visible spectroscopy and an associated calibration
curve. Release studies were carried out at 37 C in a 6 ml sink
volume of PBS. Aliquots of 1 ml were taken at the required time
and replaced with 1 ml of PBS at 37 C. Each sample of interest
was analysed in triplicate to obtain a true release prole with
associated errors.
2.2.4 Factorial design of experiments. In order to study the
eﬀects of synthetic parameters, a two level full factorial experi-
ment was set up.46 It was possible to determine the relative
magnitude of each eﬀect (e.g. change in silica precursor
concentration as detailed in Section 3.3) compared to the others
using the equation below.
effect ¼
½ðSþ level experimentsÞ  ðS level experimentsÞ
2ðnumber of factors1Þ
(1)
It was intended to use a two tailed Student's t-test to test the
hypothesis that both populations of the plus and minus levels
had the same mean. Unfortunately due to the splitting of the
population at each level by the other factors in the experiments,
a large variance was obtained causing the t-test to predict that
eﬀects were less signicant than they were in practice. Thus, in
its place we used the result from eqn (1) along with a 95%
condence interval (CI) to estimate whether the factor was
signicant. A factor which caused an eﬀect greater than either
CI was likely to have signicant inuence on the process. In
contrast, one which gave a result less than the CI was not likely
to have signicant inuence, with any observed change due to
natural variation in one, or both, factors.
2.3 Materials characterisation
Dried samples were mounted on SEM sample holders with
double sided sticky carbon tape. Upon gold coating by
sputtering, samples were analysed on a HITACHI SU-6600 Field
Emission Scanning Electron Microscope (FE-SEM) at 10 kV. The
measurement of the z-potential of silica particles was per-
formed using a Zetasizer Nano ZS from Malvern Instruments
using a disposable capillary cell. Typically, 1 ml aliquots of each
sample were injected into the capillary cell and 5–10 measure-
ments per sample were performed at 20 C. Prior to analysis,
silica particles were suspended in water by sonication.
Thermo-gravimetric analysis (TGA) was used in order to
determine the organic content of the samples. Samples were
subjected to temperatures from 25–900 C under a nitrogen
atmosphere with the temperature increasing at a rate of 10 C
min1. Porosity measurements were performed by nitrogen
adsorption using a Micromeritics ASAP 2420 porosimeter on
samples degassed for 6 h at 200 C. The data were processed
using the BET model to yield surface areas while the BJH model
was adopted for obtaining pore sizes and pore volumes.
Infrared spectra were obtained in the 4000–400 cm1 region
with a resolution of 4 cm1, by accumulating 32 scans using an
attenuated total reectance (diamond with ZnSe lens reection
ATR plate) Fourier transform infrared (ABB, MB3000 FTIR)
spectrometer. The presence of ordered pores was analysed by X-
ray powder diﬀraction using a PANalytical X'Pert Powder
diﬀractometer in the theta–theta geometry. These data were
collected under ambient conditions using Cu Ka radiation over
the range 1 # 2q # 100 using a single step size of 0.0170 2q.
The surface functionalisation of MSN samples was also
studied using titrations. 0.5 g of APMSN or SAMSN were sus-
pended in 10ml of deionised water. To this solution 20ml of 0.1
M of HCl or 0.1 M NaOH were added in 1 ml aliquots with the
pH of the solution continuously recorded. Titration using
commercially available precipitated silica was used as a control.
Prior to their use, this sample underwent an identical methanol
extraction procedure. The treated control sample was then
titrated as above.
2.4 Cytotoxicity studies
2.4.1 Maintaining cell lines. U937 human monocytes were
cultured in RPMI 1640 (with L-glutamine) growth medium
(catalogue number 12-702F, Lonza) supplemented with 10% (v/
v) foetal bovine serum, 50 units per ml penicillin, 50 mg ml1
streptomycin and 1% (v/v) non-essential amino acids. The U937
cells were maintained in the suspension in 75 cm2 asks in an
incubator (37 C and 5% CO2 in air) and were routinely
passaged every 3–4 days using a split ratio of between 1 : 15 and
1 : 20. 3T3 mouse broblasts were cultured in DMEM (catalogue
number 12-604F, Lonza) also supplemented with 10% (v/v)
foetal bovine serum, 50 units per ml penicillin, 50 mg ml1
streptomycin and 1% (v/v) non-essential amino acids. The 3T3
cells were maintained asmonolayers in 25 or 75 cm2 asks in an
incubator (37 C and 5% CO2 in air) and were routinely
passaged every 3–4 days using a split ratio of between 1 : 10 and
1 : 15.
2.4.2 Cell viability assays. U937 cells were suspended in
RPMI in round-bottom 96-well plates at 5  105 cells per ml.
Alternatively, the U937 cells were activated to become
This journal is © The Royal Society of Chemistry 2014 J. Mater. Chem. B, 2014, 2, 5028–5042 | 5031
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macrophage-like cells by incubation with 20 nM phorbol 12-
myristate 13-acetate (PMA) at 37 C for 24 h followed by a
further incubation of 72 h in fresh RPMI. The activated U937s
were then collected and seeded in RPMI onto 96-well plates at
1.25  105 cells per cm2 and allowed to attach overnight. 3T3
broblasts were seeded in DMEM onto 96-well plates at 3 
104 cells per cm2 and allowed to attach overnight. All nano-
particles were sterilised in a vacuum oven at 180 C and 60 kPa
for at least 5 h.
Immediately prior to their use in assays the prepared nano-
particles were suspended in the appropriate growth medium by
sonication to ensure their colloidal distribution. The cells in the
96-well plates were then exposed to the nanoparticles in the
appropriate growth medium solutions and incubated at 37 C
and 5% CO2 for 24 or 48 h. At each culture end-point the
medium was collected and immediately frozen at 80 C for
later analysis (ELISA). MTT or NR assays were then carried out
on the cells.
2.4.3 MTT assay. 10 mM solution of MTT in PBS pH 6.75
was made up and ltered through a 0.2 mm lter. Once the
medium had been removed from the 96-well plates 50 ml MTT
solution was added to each well. The plates were then incubated
for a further 4 hours at 37 C before removing the MTT solution.
200 ml dimethylsulfoxide (DMSO) was then added to each well to
dissolve the formazan product and was mixed to an even colour.
Absorbance was read at 540 nm and results were compared with
ANOVA followed by Dunnett's test.
2.4.4 Neutral red (NR) assay. 5 mg NR was dissolved in 100
ml PBS and incubated overnight at 37 C before passing it
through a 0.2 mm lter. Destain was made from ethanol, glacial
acetic acid, and dH2O at a ratio of 50 : 1 : 49. Once the medium
had been removed from the 96-well plates 100 ml NR solution
was added to each well. The plates were then incubated for a
further 3 hours at 37 C. NR solution was then removed and the
cells were washed once with PBS (200 ml per well). At this stage
100 ml destain was added to each well and the plate shaken until
a homogenous colour was achieved in all wells. Again the
absorbance was read at 540 nm. Results were compared with
ANOVA followed by Dunnett's test.
2.4.5 Enzyme-linked immunosorbent assay (ELISA). Ready-
Set-Go!® ELISA kits for human cytokines interleukin-2, inter-
leukin-6, tumour necrosis factor-a and interferon-g were
purchased from eBioscience® (catalogue numbers 88-7025, 88-
7066, 88-7346 and 88-7316 respectively), and ELISAs were per-
formed on the supernatant from the cell viability studies
precisely according to the manufacturer's instructions.
2.4.6 Epiuorescence microscopy. To allow the U937
monocytes to attach to the tissue culture plastic, 35 mm2 Petri
dishes were coated with 1 ml 0.01% (v/v) poly-L-lysine. Aer 10
minutes the poly-L-lysine was aspirated and Petri dishes were
allowed to dry at room temperature overnight. U937 monocytes
were then suspended in RPMI (containing nanoparticles where
appropriate) at 5  105 cells per ml and incubated at 37 C and
5% CO2 for 24 h. 3T3 cells were seeded onto 35 mm
2 Petri
dishes at 2  104 cells per cm2, and were allowed to adhere
overnight at 37 C. Their respective growth media were then
removed and replaced with fresh media containing
nanoparticles, and the cells were incubated for a further 24 h
at 37 C and 5% CO2.
Acridine orange (AO) and propidium iodide (PI) were
prepared at 20 mg ml1 and 100 mg ml1 respectively in PBS pH
7.4. They were then mixed together to form a 1 : 1 AO + PI
solution. The medium was rst removed from the Petri dishes
and the samples washed three times with PBS pH 7.4. 1 ml of
the AO + PI solution was then added to samples and they were
incubated in the dark for 1 min at room temperature. Samples
were given a further three washes with PBS before viewing in
PBS with a 20 (0.5 NA) water lens using a Zeiss AxioImager Z1
wide eld uorescence microscope and the digital imaging
system. Fluorescence was excited using a mercury lamp and
emission was recorded using a uorescein isothiocyanate
(FITC)/rhodamine lter block (485/515–530 nm; 546/580–
563 nm).
2.4.7 Light microscopy. U937 cells were suspended in
RPMI in 24-well plates at 4  105 cells per ml, with nano-
particles dissolved in the RPMI where appropriate. The cells
were incubated at 37 C and in 5% CO2 for 5 days, and images of
the cells were taken at the same time each day using a Nikon
microscope and the digital imaging acquisition system.
3. Results and discussion
3.1 GN as a drug delivery system
In order to engineer GN for drug delivery applications, it is
important to understand the eﬀects of DDS fabrication
parameters on drug loading and release. Initially, calcein was
chosen as a model hydrophilic drug molecule. The bioinspired
silica synthesis is known to be facilitated by ‘additives’24 and we
selected diethylenetriamine (DETA), tetraethylenepentamine
(TEPA), pentaethylenehexamine (PEHA) and poly(allylamine
hydrochloride) (PAH); these additives had been shown to
catalyse the formation of silica from a solution of silicates, while
oﬀering variation in the properties of silica produced.24,28
Fig. 1a inset shows images of GN prepared with or without
the calcein and the presence of drug in the orange silica is clear
when compared to white silica powder that is typically produced
without any drug. Fig. 1a shows percentage weight of drug in
drug–silica samples (i.e. calcein content) and the fraction of
initially added drug which loaded (i.e. loading eﬃciency). It can
be seen that both drug content and drug loading eﬃciency is
heavily inuenced by the presence of additives, although the
additive with the smallest molecular weight (DETA) showed the
least inuence. Additionally, a clear correlation between the
number of nitrogen atoms per additive molecule and drug
content was not observed. The highest drug content (30 wt%)
was obtained for samples prepared in the presence of TEPA
while the highest loading eﬃciency of 40% was recorded for
TEPA and PAH mediated silica. These loading gures are
signicantly higher than those reported in the literature for
unfunctionalised or functionalised mesoporous silicas (typi-
cally 2–5 and20 wt% respectively).15,16 This result, which is not
unexpected, highlights one of the advantages of using GN for
drug delivery. The reason behind such high drug loading is that
the drug is present during GN formation and can easily occupy
5032 | J. Mater. Chem. B, 2014, 2, 5028–5042 This journal is © The Royal Society of Chemistry 2014
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pores. This also enables slow release by modulation of drug
release rates using GN synthetic chemistry, as detailed in
Sections 3.2 and 3.3.
It is interesting to note that both the drug content and
loading eﬃciency for samples prepared with PEHA were lower
than those prepared with TEPA. It has been reported that PEHA
catalyses silica formation about 3 times faster than TEPA, while
the silica prepared in the presence of PEHA is essentially non-
porous compared with TEPA–silica which is porous.29,30 It then
appears that PEHA does not allow the drug molecules to enter
silica as much as TEPA due to rapid silica condensation, while
the rate of silica formation with TEPA appears to be optimum
for maximising drug loading.
In order to examine if the presence of drug aﬀected silica
precipitation, the amounts of silica precipitated in the presence
and absence of the drug were measured by weighing the nal
product and subtracting the amount of drug loaded. For small
additives (DETA, TEPA and PEHA), the presence of the drug did
not aﬀect the silica yield signicantly (compare white and grey
bars for each additive in Fig. 1b). Similarly, the silica yield of the
control sample (prepared without any additive, essentially a gel
collected aer 7 days) was not inuenced by the presence of the
drug (data not shown). However, when a polymeric additive
(PAH) was used, a signicant increase in silica yield was
observed in the presence of the drug. This is probably due to a
co-operative eﬀect from the interactions of negatively charged
calcein and positively charged PAH molecules under synthetic
conditions (pH 7). Such interactions have been previously
reported in the one-step fabrication of the drug in silica gels.17
Although a similar eﬀect may be expected with small additives,
the higher charge density in polymeric amines (PAH in this
case) is known to exhibit stronger interactions with oppositely
charged biomolecules, micelles, colloidal particles, etc.47–50
The release of calcein (Fig. 2) shows that the particles
prepared with longer polyamines gave more sustained release.
It is evident that the chemistry of the synthesis of GN, the
additives used in particular, was able to modulate the drug
release proles all the way from instantaneous release to sus-
tained release over weeks. The control sample prepared with no
additive exhibited a release prole reminiscent of the
Fig. 1 (a) Loading and loading eﬃciency of drug for each bioinspired
additive (see text for details), inset shows images of ﬁnal products with
(left) and without calcein. (b) The eﬀect of the presence of drug
molecules on silica yield.
Fig. 2 Overall (a) and initial (b) release proﬁles of calcein from GN
synthesised using several additives. Note the diﬀerence in X-axis units
between (a) and (b). The ﬁtted lines are not showing the Korsmeyer–
Peppas model, see Section 3.2 for details.
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dissolution prole of free calcein, which means that the control
sample did not oﬀer any regulation over release. Furthermore,
the total amount of drug released had a strong correlation with
the number of nitrogen atoms present in each additive (Fig. 3a).
It is important to note here that the nal concentration of
nitrogen was kept constant for each additive used. This means
that the number of additive molecules decreased as the additive
size increased, while the amine/charge density increased
signicantly with the size of the additive molecule. For example,
at the same nitrogen concentration, there were twice as many
DETA molecules (three amines) than PEHA (six amines). The
eﬀects of change in amine size on silica formation have been
extensively studied and reported in the literature,29,30 while the
eﬀects on the amine–drug interactions are discussed in subse-
quent sections. An important point to note here from the drug
release results is that the chemistry of the additives can be used
to control the release prole by regulating the structure of GN
produced and/or its interactions with the drug.
3.2 Drug release mechanisms
Using the Korsmeyer–Peppas model (a single exponential), we
can t the above release data and obtain parameters which
correspond to physical characteristics of the system and enable
quantitative comparison between samples.51,52
Mt
MN
¼ K  tn (2)
where Mt is the mass of drug released at time t; MN is the mass
of drug released at equilibrium; K is a rate constant character-
izing the carrier and the drug system; t is time and n is the
diﬀusional exponent – characterising the method of release
from the carrier. For the validity of this model, only the rst
60% of release should be tted to eqn (2).51 Therefore we
applied this equation to the rst 60% of the recorded release
data and reasonable ts to the experimental data were observed
(R2 > 0.98), with an exception of the PAH sample (Fig. S1†).
The values of the rate constant K and exponent n are pre-
sented in Table S1.† FromFig. 3b once againwe see that the drug
release (release rate constant K) wasmodulated by the chemistry
of the additive used in silica synthesis. Values of n correspond to
the release mechanism as per Table S2† reproduced from Ritger
and Peppas.51 In all cases n was between 0.5 and 1, whichmeans
that the drug release followed non-Fickian diﬀusion. These
values are typical of those given in the literature.53 This release
pattern expected to be Fickian diﬀusion only applies where the
ux is limited by the diﬀusion through the medium and is less
likely to be applicable in our case where the loaded drug must
rst diﬀuse from the internal pores of the silica matrix followed
by its diﬀusion from the external surface into the bulk liquid,
consistent with the literature.18 DDS prepared in the presence of
TEPA, PEHA and PAH exhibited similar exponents, suggesting
that the release mechanisms were identical. For TEPA, PEHA
andPAH the release ismuch slower withmuch higher exponents
(n) of release. It is therefore possible that another step in the
release process is limiting for these samples.
The work of Peppas et al. was originally composed for so
polymers which are close to their glass transition temperatures
and any non-Fickian behaviour was attributed to polymer
swelling and relaxation in the solution.54 This will not apply to
the structure of the silica formed in this work, given that at 37
C silica remains a hard, covalently bound, network. Another
commonly used model for describing drug release is the
Higuchi equation.55 This model is essentially a special case of
the Peppas model where n¼ 0.5. However, from Table S1† it can
be seen that for GN DDS, n > 0.5 and therefore the Higuchi
model is unlikely to t the release data from Fig. 2. Although,
this model describes diﬀusion of the drug from smooth
surfaces and typically only ts the rst 15% of the data, it has
been widely applied to drug release from mesoporous silicas,
which are far from smooth surfaces.19,20,56
It is clear that neither the Higuchi nor Peppas models can
adequately describe the entire prole for drug release (100% of
the release data), with PAH being especially poorly modelled
(Fig. S1†). In addition, these models are insuﬃcient to fully
describe non-ideal porous materials such as silica. Therefore an
empirical double exponential functionwas employedof the form:
Mt ¼ M0 + M1(1  e
x/t1) + M2(1  e
x/t2) (3)
where M0 is the oﬀset from the origin at x ¼ 0; M1 is the mass
released in the rst exponential; t1 is the duration of the rst
Fig. 3 (a) Mass of drug released, normalised to the control sample (n ¼ 0) as a function of nitrogen atoms per additive molecule. (b) The release
rate constant (K) obtained from ﬁtting the release data to the Korsmeyer–Peppas Equation (eqn (2)). (c) The amount of burst release as a function
of nitrogen atoms per additive molecule obtained by ﬁtting the release data to a double exponential eqn (3). Note that the ﬁnal concentration of
nitrogen was kept constant for each additive used.
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exponential; M2 is the mass released in the second exponential
and t2 is the duration of the second exponential.
Fitted curves are shown as dashed lines in Fig. 2 and a
number of advantages were apparent with this model. The R2
values were always greater than 0.99 and the equation modelled
the entire release prole, unlike only parts modelled by the
Korsmeyer–Peppas model (modelled 60% of the data54) or the
Higuchi model (modelled 15% of data55). Furthermore, it
aﬀords the quantication of distinct release mechanisms that
are typically observed with non-ideal materials arising from
internal porosities.57 This double exponential suggests that
calcein release is a two stage process for GN, which can aﬀord a
clear distinction between burst and sustained release. We
attribute the rst, faster release stage to the drug that is weakly
physisorbed on the external surface of GN. The slower and
sustained release of the drug in the second stage could be
attributed to drug–additive interactions, internal porosity of GN
or both. As a result, drug release will be expected to be a two
stage process, which can be accurately modelled with a double
exponential equation. Although perhaps new to the drug
delivery eld, suchmodels are commonly applied inmany other
areas of research such as reaction kinetics and dissolution
processes.58
The release of the drug from within the network of pores,
which is a common feature of GN,41would present an additional
barrier to mass transfer for the release of drug molecules when
compared to the drug adsorbed simply on external surfaces of
silica particles. This is particularly important to note since the
drug is loaded as silica forms and therefore it is highly likely
that the drug molecules are located in the internal voids
between primary particles. Interactions between themodel drug
and the additive are highly likely, as reported previously for a
silica gel DDS,17 and were also evident from the results dis-
cussed in Section 3.1. A stronger interaction would explain a
slower second exponential stage of release. This also explains
why the control sample, where no amine groups were present
for interactions, was well described by a single exponential
function (i.e. Korsmeyer–Peppas model), which represents drug
loading via physisorption on the surface of the control sample.
Applying eqn (3) to decouple burst and sustained release, we
observed that GN allows control over the amount of drug
released in a sustained fashion (Fig. 3c). The fraction of the drug
that was weakly physisorbed on silica (burst release) decreased
with increasing amine chain length. This observation further
strengthens the tunability of GN for drug delivery and also
highlights the importance of the interaction of the drug with
amines occluded in silica, which were further investigated and
the results are presented in Section 3.3 below.
3.3 The role of chemistry in controlling drug delivery
A closer inspection of the drug loading and release data indi-
cates that entrapping the drug with PAH showed a promising
loading capacity as well as a release prole in terms of sustained
release when compared to other additives studied herein.
Therefore PAH was selected for further systematic investiga-
tions in order to study the eﬀect of synthesis parameters on
drug loading and release. A two level full factorial experiment
was set up using eqn (1) as described in Section 2.2.4 (ref. 46)
with the three key parameters (reaction time, [Si] : [N] molar
ratio r and silica precursor concentration [Si]) at “high” (+) and
“low” () levels as shown in Table 1. The eﬀects of these
parameters were quantied by measuring silica yield, drug
loading and drug release. Such factorial design of experiments
and analysis of results allow the identication of single, or a
group of, parameters that signicantly aﬀect the outcomes.
Fig. S2† shows the eﬀect of these factors on the silica yield for
each experiment. Assessing the graph rst we can see that in all
experiments silica yields were similar (70–80%) with the
exception of experiment D6 where the yield never exceeded
60%. No grouping of the bars in Fig. S2† is obvious, suggesting
that no large changes in silica yield are aﬀorded by changing the
parameters under study. To account for any possible skewing of
the data towards any single parameter, we can discount one
factor at a time and establish a series of second level two factor
tests. This analysis suggests that there were no diﬀerences
observed beyond the 95% CI (Fig. S3†). It is therefore likely that
the silica yield is uninuenced by the factors under study.
Fig. 4a shows the eﬀect of experimental parameters on the
entrapment of calcein within the optimization experiments. A
clear periodic trend was observed with higher drug loading
associated with experiments with higher [Si] : [N] ratios (r). This
is conrmed by further analysis which showed a large magni-
tude of the eﬀect of changing the ratio r, far in excess of the 95%
CI (Fig. 4b). In this case the molar ratio r had a signicant eﬀect
with a ratio of 2 giving a much higher entrapment than 1 : 1
Table 1 Design of experiments for identifying key parameters aﬀecting GN yield, drug loading and drug release
Experiment ta [Si]b rc t4 [Si] interaction t4 r interaction [Si]4 r interaction t4 [Si]4 r interaction
D1    + + + 
D2   + +   +
D3  +   +  +
D4  + +   + 
D5 +     + +
D6 +  +  +  
D7 + +  +   
D8 + + + + + + +
a + level ¼ 5 minutes,  level ¼ 1 minute. b + level ¼ 50 mM,  level ¼ 30 mM. c + level ¼ 2 : 1,  level ¼ 1 : 1.
This journal is © The Royal Society of Chemistry 2014 J. Mater. Chem. B, 2014, 2, 5028–5042 | 5035
Paper Journal of Materials Chemistry B
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
7 
Ju
ne
 2
01
4.
 D
ow
nl
oa
de
d 
on
 0
5/
08
/2
01
4 
15
:4
4:
08
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
ratio. None of the other synthetic parameters appeared to
signicantly aﬀect drug loading. In order to investigate whether
the absolute nitrogen concentration had any eﬀect (which could
be convoluting the apparent eﬀect of r), four nitrogen concen-
trations used were explored and their eﬀects on drug
entrapment were measured (Fig. 4c). The eﬀect of nitrogen
concentration was clear: below a critical concentration of 25
mM, enhanced drug loading was observed. The changes caused
by r or nitrogen concentration are likely to be due to the well-
known eﬀect of amines on the physical properties of GN such as
porosity30 and also perhaps drug–additive interactions. While
identifying conditions for achieving high drug loading eﬃ-
ciencies without aﬀecting the yield of silica formation, these
results suggest that both the [Si] : [N] ratio and the absolute
nitrogen concentration are important.
The release of calcein from these optimization experiments
was also recorded (Fig. 5) where two groupings of release
proles were obvious. The four curves above the dashed line,
where the higher amounts of the drug were released, corre-
spond to higher concentration of the silica precursor (and in
turn higher r). Although the exact mechanism of the depen-
dence of drug release on silica precursor concentration is not
clear at this point of time, we speculate the following from the
information available in the literature. At lower [Si] the forma-
tion of silica is slow, which allows suﬃcient opportunity for the
drug to be deeply entrapped and “sealed” inside silica. On the
Fig. 4 (a) Drug loading achieved in the factorial experiments. (b)
Results from factorial experiments designed to establish key param-
eter(s) that have a signiﬁcant eﬀect on drug loading. (c) Further
exploration of the eﬀect of amine concentration on drug loading.
Fig. 5 Overall (a) and initial (b) release of the drug from the samples
prepared in the factorial experiments. Note the diﬀerent X-axis units in
(a) and (b). The dashed line separates two sets of results, see the text.
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other hand, at high concentrations of the silica precursor, silica
formation is very rapid where the drug is only loosely bound and
hence available for release. Nonetheless, it is clear that higher r
is benecial for both drug loading eﬃciency and drug release.
This again clearly supports the notion that the additive has a
pronounced eﬀect on both silica formation and drug loading/
release.
Having identied the key parameters controlling the fabri-
cation of the delivery system, we sought to investigate the eﬀects
of the synthesis procedures on the fabrication as a potential
factor which could aﬀect the product. It is clear that in GN
synthesis, the interactions between the amine and silicates are
important, while the results above indicate that there is also a
possibility of the occurrence of amine–calcein interactions. In
particular, the order of addition of precursor, additive and drug
was investigated systematically and the experimental design is
detailed in Table 2. The silica yields and drug loading eﬃcien-
cies for these experiments are shown in Fig. 6.
It is evident that the order of adding each component to the
reaction system clearly has a profound eﬀect on both silica yield
(modulated from 0 to 90%) and drug loading. Surprisingly,
neutralizing additive and silicate solutions before mixing the
reactants did not produce any silica recoverable by centrifuga-
tion (experiments O4–O6). If we consider experiments O1, O2
and O3, the mixing of PAH and silicate occurs in a basic solu-
tion at around pH 12. The conjugate acid–base equilibrium for
PAH, calcein and orthosilicic acid can be written as below along
with their reported pKa values:
[CH2CH(CH2NH
+
3 )]n#
[CH2CH(CH2NH2)]n + nH
+ pKa: 9.5 (ref. 59) (4)
C30H26N2O13# [C30H25N2O13]
 + H+ pKa: 6.67 (ref. 60) (5)
SiO4H4# SiO4H3
 + H+ pKa: 9.8 (ref. 61 and 62) (6)
Applying the Henderson–Hasselbalch equation at pH 12, it
appears that PAH is not protonated (>99% as –NH2), the
majority of calcein is deprotonated (>99% as –COO) and silicic
acid is deprotonated (>99% as^SiO). Therefore, there will not
be any electrostatic interactions between the amine and calcein,
while it is known that at pH 12, the formation of the silica
particles will not occur.62 As the pH is adjusted to 7, PAH will
become extensively protonated (>99% as –NH3
+), and the
protonated amines will be available to interact with silica and
will not be associated or “blocked” by calcein prior to silica
formation. Strong electrostatic interactions between PAH and
silicates occur, leading to rapid silica precipitation. In experi-
ments O4, O5 and O6 the protonation states of amine, calcein
and silicic acid are signicantly diﬀerent before the solutions
are mixed. Each solution is rst neutralised to pH 7 and then
mixed, which can cause signicant association between
protonated amines (>99% protonation) and deprotonated cal-
cein (68% as –COO). This can result in no silica precipitation
by the restriction of amine–silicate interactions before the silica
formation can start. Interestingly, under identical conditions,
when PAH is replaced by PEHA (experiment O7), a signicant
amount of silica formation was observed (Fig. 6), which can be
explained by the diﬀerences in the protonation between PAH
and PEHA. It has been reported that at pH 7, PEHA is only 50%
protonated29,30 in contrast to >99% protonated PAH. This leaves
Table 2 Stepwise details of experiments designed to understand the eﬀects of the order of addition of reagents
Step 1 Step 2 Step 3 Step 4
O1 Drug + silicate solution Dissolved PAH added to
solution from step 1
pH adjusted to 7 N/A
O2 Drug + PAH solution Dissolved silicate added to
solution from step 1
pH adjusted to 7 N/A
O3 PAH + silicate solution pH of solution from step 1
adjusted to 7
Dissolved drug added
immediately to solution
from step 2
N/A
O4 Drug + silicate solution pH of solution from step 1
adjusted to 7
pH of PAH solution adjusted
to pH 7
Solutions from
steps 2 and 3 mixed
O5 Drug + PAH solution pH of solution from step 1
adjusted to 7
Silicate solution acidied to
pH 7
Solutions from
steps 2 and 3 mixed
O6 pH of PAH solution adjusted
to pH 7
Silicate solution acidied to
pH 7
Solutions from step 1 and 2
mixed
N/A
O7 Identical to O5 but PAH replaced with PEHA.
Fig. 6 The eﬀect of the order of adding reactants on the silica yield
and drug loading eﬃciency.
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PEHA–calcein interactions weak and allows PEHA–silicate
interactions to occur, resulting in silica precipitation. These
results have helped optimise the order of mixing of reagents in
fabricating DDS.
3.4 GN performance in delivering therapeutically useful
drugs
The mechanisms underpinning the drug release were investi-
gated and we presented how ne tuning the chemistry of
synthesis of GN–DDS can allow us to achieve desired designs for
drug delivery systems. In this section, we sought to utilise these
results and apply them for developing DDS for a number of
therapeutically useful drugs while also exploring any potential
limitations to the GN-based DDS. A series of pharmaceutically
active small molecules were chosen to reect a range of
hydrophobicities: atenolol (log P ¼ 0.16), pindolol (log P ¼
1.75), ibuprofen (log P ¼ 3.97) and nile red (log P ¼ 5.0).
Ibuprofen is a non-steroidal anti-inammatory agent, atenolol
and pindolol are betaadrenoceptor antagonists (beta blockers)
and nile red is a dye which was used to emulate a very hydro-
phobic molecule. The loading for each of these molecules was
very high (between 87 and 100%), while there were diﬀerences
in both the release proles and amounts released were observed
(Fig. 7a).
With an exception of Nile red, the drug release was sustained
over several days. Although the amount of drug released could
be improved, diﬀerences in the release proles were observed
between the drugs under consideration. Since the synthesis of
GN–drug systems occurred entirely in aqueous solutions, the
hydrophobicity or water solubility of each drug may be regu-
lating their release. In order to test this hypothesis, solubility
data for each compound were obtained from the literature,63
and plotted with the per cent drug released (Fig. 7b). From these
data, it is evident that the water solubility of the drugs strongly
inuences the amount of drug released, with the least soluble
drug, Nile red, preferring to stay inside silica with no release
occurring. These results will be of immense importance in
designing GN as DDS in future, while they also highlight a
limitation of the GN systems such that the chemistry of GN will
require further consideration in future work in order to eﬃ-
ciently load and release hydrophobic drugs – an important class
of drugs (e.g. anticancer drugs).
3.5 Toxicity results
In order to test the cytotoxicity of GN, PAH–GN and PEHA–GN
were selected due to their encouraging release proles shown in
Fig. 2. The results were compared with a colloidal Sto¨ber silica
sample, and twoMSN: APMSN and SAMSN (amino- and sulfonic
acid-functionalised MCM-41 respectively, see Experimental
section). Sto¨ber silicas form excellent comparative standards.
The functionalised MCM-41 have been preferred DDS over
unfunctionalised silicas due to their reported enhanced drug
loading capacity from strong interactions with drug molecules,
improved biocompatibility and potential in targeted delivery.4,6
The toxicity of nanomaterials can result in a number of
eﬀects including damage to membranes, changes in protein
folding, DNA mutation, blood abnormalities and oxidative
stress injuries.21,64 Although extensive analysis is necessary to
fully understand the toxic eﬀects, measurements of cell viability
and proliferation can provide an indication of the safety of
nanomaterials. Hence cell viability assays were employed in this
study using both murine 3T3 broblast cells, a standard cell
line widely used for in vitro cytotoxicity evaluation as recom-
mended by ISO 10993, and U937 human monocyte-like cells in
both rested and activated states. U937 cells were activated to
phagocytotic macrophage characteristics, and comparison of
toxic responses in resting and activated cells allows the contri-
bution of nanoparticle internalisation by phagocytosis to be
determined.
In the case of broblasts, Sto¨ber particles reduced cell
viability to 80% of the control (cell lines without silica parti-
cles) even at concentrations as low as 5 mg ml1 (Fig. 8a). The
observed mild toxicity of Sto¨ber silica at low concentrations is
consistent with the literature.65,66 Upon increasing the silica
dose, the cell response was unchanged and hence appeared to
be independent of Sto¨ber silica concentration. On the other
hand, Sto¨ber particles were not found to reduce cell viability of
the human monocytes (Fig. 8b and c). Such cell-line dependent
Fig. 7 (a) Release proﬁles for several drugs from GN. (b) The total
amount of drug released fromGN as a function of the solubility of each
drug molecule, relative to Nile red.
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responses have been well-documented. For example, Yu et al.
reported that a range of silica nanoparticles did not have any
toxic eﬀects on tumour cells while a dramatic reduction in cell
viability was recorded for macrophages, probably reecting
intracellular uptake of particles by phagocytosis in the latter
cells.67 We observed that the Sto¨ber silica concentration to
reduce cell viability to 50% (IC50) was >500 mg ml
1 (Table 3).
Surprisingly, in the current study, PEHA–GN did not show
any toxic eﬀects, to either broblasts or human monocytes in
the resting state, even when silica concentrations as high as 500
mg ml1 were used (Fig. 8a and b). This observation is particu-
larly interesting since PEHA (i.e. without silica) was toxic to the
same cell lines (Fig. S4†), thus suggesting that when trapped in
silica, PEHA becomes less toxic. In contrast, PAH–GN, and both
MSN samples, reduced cell viability signicantly in both cell
lines. These diﬀerences in toxicity are illustrated in the micro-
graphs presented, where the cell number is markedly depleted
in samples treated with both MSN particles (Fig. 9a), and the
uorescent staining shows an increased number of dead cells,
their nuclei stained red with propidium iodide (Fig. 9b and c).
The IC50 values listed in Table 3 imply that MSN were clearly
more toxic than Sto¨ber silicas or either of the GN.
No signicant diﬀerences in cell viability for Sto¨ber, MSN
and PAH–GN samples were observed when the human mono-
cytes were activated, even at the highest silica concentrations
investigated. However, reduced cell viability was observed for
activated monocytes in the presence of PEHA–GN, which had
previously shown no toxicity to resting monocytes (Fig. 8c).
Although the IC50 of 200 mg ml
1 for PEHA–GN indicates that
toxicity is not a realistic safety issue for the exposures
Fig. 8 Cell viability upon incubation of silica particles with (a) 3T3, (b) U937 in the resting state and (c) U937 in the activated state.
Table 3 IC50 values for silica particles (mg ml
1 of silica concentration
required to reduce cell viability to 50%)
Cell lines
Samples 3T3 U937 rested U937 activated
Sto¨ber >500 [500 [500
AP–MSN 20 20 25
SA–MSN 20 20 25
PAH–GN 100 200 25
PEHA–GN [500 [500 200
Fig. 9 Optical (a) and ﬂuorescent (b and c) microscopy images of cells with (50 mg ml1) and without silica particles for U937 cells in the resting
state after 5 days (a) or 1 day (b) in culture, and 3T3 cells (c) after 1 day in culture. Images in (a) are presented at 300 magniﬁcations.
This journal is © The Royal Society of Chemistry 2014 J. Mater. Chem. B, 2014, 2, 5028–5042 | 5039
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encountered inmost biomedical uses, it is comparable to values
reported for most silica particles.65,67 The increased sensitivity of
activated monocytes to PEHA–GN probably occurs due to
intracellular access of particles following phagocytosis, leading
to some specic toxic response inside the cells.64,68
Inammatory responses to nanoparticles are known to cause
considerable adverse eﬀects in vivo, and in order to predict the
likelihood of these the release of inammatory cytokines,
interleukins, tumour necrosis factor-a (TNF-a) and interferon-g,
in response to nanoparticle exposure are commonly measured
by specic ELISA.21 TNF-a secretion has been reported to
increase by 20-fold in the presence of silica particles.69However,
in this study, only at high levels of exposure $500 mg ml1
detectable cytokine release was measured at either 24 or 48 h
treatment, although transient trace secretion of all four medi-
ators was induced by PAH–GN at 24 h, but not at 48 h (data not
shown). It is evident that none of the samples used induced
secretion of inammatory cytokines at the concentrations
proposed for use in DDS.
Physicochemical properties of nanomaterials such as
chemical composition, particle size, porosity and surface
functionalisation, are important when considering cell
responses.23 “Silica” represents a vast number of materials with
distinct structures and properties, including crystalline (e.g.
quartz), amorphous, porous, colloidal, gels, etc.7,8 They diﬀer
from one another in the sizes of particles and aggregates,
porosities, the level of hydration, and the surface chemistry.
These seemingly subtle diﬀerences which mainly arise from the
processing conditions, can manifest themselves in signicant
ways such as drastic diﬀerences in the biodegradation9 and
biological response.70,71 For Sto¨ber silicas, there was no evidence
of the presence of organics from Infrared spectroscopy (FTIR),
while small amounts of organics were detected in all other
samples, as expected (also veried from thermal analysis,
Fig. S5†). A combination of surface sensitive ATR-FTIR, zeta
potential measurements and titrations revealed that Sto¨ber
silica possessed only silanol (Si–OH) and siloxide (Si–O)
groups on the surface with a zeta potential of 48 mV (Fig. S5
and Table S3†). SAMSN possessed acidic surfaces and negative
zeta potential, which was also conrmed by titration, while
APMSN had a basic surface with positive zeta potential, as
expected (Fig. S6 and Table S3†). Interestingly, PEHA–GN
exhibited a slightly positive zeta potential (z¼ +10mV), perhaps
from surface-bound PEHA, while PAH–GN had a slightly nega-
tive zeta potential (z ¼ 18 mV), indicating that the majority of
PAH remains inside the sample. It has been reported that
positively charged silica particles are relatively less toxic,67,72
which explains the diﬀerences in toxicity between PEHA–GN
and PAH–GN. However, AP–MSN particles, which were also
positively charged were found to be highly toxic (IC50 z 20 mg
ml1) compared with the positively charged PEHA–GN (IC50[
500 mg ml1 for both 3T3 and resting U937 cell lines).
The only diﬀerences between both positively charged silica
samples (PEHA–GN and APMSN) were their porosities and
particle sizes. It was found that MSN samples exhibited large
surface areas (z500–700 m2 g1) and pore volumes with narrow
and ordered mesopores of2.6 nm (Fig. S7–9 and Table S3†). In
contrast, GN appeared to have low surface areas (<55 m2 g1),
broad pore size distribution and disordered pores, which is
consistent with the literature reports.41 Despite low surface
areas, the drug loading in GN was more than twofold higher
compared to that reported in the literature (see Section 3.1).
Although low surface area may aﬀect drug release, it has been
reported that surface area of GN can be readily controlled.30
Furthermore, there were variations in the particle sizes between
samples, which ranged from 130 nm (PAH–GN) to 720 nm
(SAMSN) (Fig. 10). SEM revealed that the particles were present
as aggregates, which was also conrmed by DLS analysis (data
not shown) with a broad distribution of particle size, suggesting
aggregated systems (with an exception of Sto¨ber particles). It is
therefore clear that in this study, the cells were not interacting
with individual nanoparticles but rather with aggregates of
nanoparticles which were several hundreds of nanometers or
even micrometers in size. This observation is not unexpected
since nanoparticles are unlikely to avoid aggregation in complex
biological media containing a wide variety of ions and
biomolecules11,73 and hence our systems are thought to closely
represent realistic conditions. There was no apparent trend
Fig. 10 Scanning electronmicrographs of silica particles used: (a) Sto¨ber silica, (b) PEHA–GN, (c) PAH–GN, (d) APMSN and (e) SAMSN. Scale bars
¼ 500 nm except 1 mm for (b).
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between particle size and their toxicity, which is contrary to
most literature reports.65 However, the particles reported in the
literature are much smaller with negligible aggregation
compared to those reported here.
4. Conclusions
The main conclusions from this work are threefold, as listed
below.
(1) We have shown that for the model hydrophilic drug
molecule calcein, additive chemistry and synthesis/loading
method can be used to tailor the release prole, particularly in
the burst time frame (rst few hours). This shows that GN DDS
have the potential to be tailorable in release prole terms
without the need for extensive synthetic routes/
functionalisations.
(2)We have shown that GNDDS have the potential to perform
sustained release with drug molecules which cover a range of
log P values and this, coupled with point 1, and the ease of
synthesis, makes GN a viable alternative to MSN systems which
have traditionally dominated the DDS eld with regard to silica.
(3) GN were least toxic silica particles in most experiments,
while, both types of MSN particles showed substantially
reduced cell viability, even at low concentrations. Furthermore,
GN exhibit additional benets such as green synthesis and ease
of functionalization. This strengthens the argument for future
use of GN in DDS and other biomedical applications.
Further studies using a wider expanse of cell lines, organ
baths and animal models are required to fully understand the
GN and optimise administrative routes of GN DDS but current
in vitro cell data appear to be highly promising.
Acknowledgements
The authors thank the Department of Chemical and Process
Engineering, Strathclyde Institute of Pharmacy and Biological
Science, The Bridging the Gap award and the EPSRC Doctoral
Training Centre in Medical Devices for funding. We also thank
the Advanced Materials Research Laboratory for the SEM and
TGA analyses and the Department of Pure and Applied Chem-
istry for access to XRD facility. Dr Thomas Yip and Colin
McKinstry are thanked for their help with XRD and nitrogen
adsorption.
References
1 A. Nel, T. Xia, L. Madler and N. Li, Science, 2006, 311, 622.
2 C. A. Schutz, L. Juillerat-Jeanneret, H. Mueller, I. Lynch and
M. Riediker, Nanomedicine, 2013, 8, 449.
3 T. Doane and C. Burda, Adv. Drug Delivery Rev., 2013, 65, 607.
4 F. Q. Tang, L. L. Li and D. Chen, Adv. Mater., 2012, 24, 1504–
1534.
5 S. Simovic, N. Ghouchi-Eskandar, A. M. Sinn, D. Losic and
C. A. Prestidge, Curr. Drug Discovery Technol., 2011, 8, 250–
268.
6 A. E. Garcia-Bennett, Nanomedicine, 2011, 6, 867.
7 C. J. Brinker and G. W. Scherer, Sol-Gel Science, Academic
Press, Boston, 1990.
8 R. K. Iler, The Chemistry of Silica, John Wiley & Sons, New
York, 1979.
9 Q. J. He, J. L. Shi, M. Zhu, Y. Chen and F. Chen, Microporous
Mesoporous Mater., 2010, 131, 314.
10 E. M. Carlisle, Science, 1970, 167, 279.
11 F. Sharif, F. Porta, A. H. Meijer, A. Kros and
M. K. Richardson, Int. J. Nanomed., 2012, 7, 1875.
12 S. Tan, Q. X. Wu, J. Wang, Y. L. Wang, X. L. Liu, K. K. Sui,
X. Y. Deng, H. F. Wang and M. H. Wu, Microporous
Mesoporous Mater., 2011, 142, 601–608.
13 T. T. Wang, F. Chai, Q. Fu, L. Y. Zhang, H. Y. Liu, L. Li,
Y. Liao, Z. M. Su, C. A. Wang, B. Y. Duan and D. X. Ren, J.
Mater. Chem., 2011, 21, 5299–5306.
14 P. Horcajada, A. Ra´mila, G. Fe´rey and M. Vallet-Reg´ı, Solid
State Sci., 2006, 8, 1243–1249.
15 S. W. Song, K. Hidajat and S. Kawi, Chem. Commun., 2007,
4396–4398.
16 C. Y. Lai, B. G. Trewyn, D. M. Jeinija, K. Jeinija, S. Xu,
S. Jeinija and V. S. Y. Lin, J. Am. Chem. Soc., 2003, 125,
4451–4459.
17 G. Paul, J. Heimink and H. Koller, Chem. Mater., 2008, 20,
5083–5089.
18 W. Shaobin, Microporous Mesoporous Mater., 2009, 117, 1–9.
19 I. Izquierdo-Barba, A´.Martinez, A. L.Doadrio, J. Pe´rez-Pariente
and M. Vallet-Reg´ı, Eur. J. Pharm. Sci., 2005, 26, 365–373.
20 P. Horcajada, A. Ra´mila, J. Pe´rez-Pariente and R. Vallet,
Microporous Mesoporous Mater., 2004, 68, 105–109.
21 H. Meng, T. Xia, S. George and A. E. Nel, ACS Nano, 2009, 3,
1620.
22 S. P. Hudson, R. F. Padera, R. Langer and D. S. Kohane,
Biomaterials, 2008, 29, 4045.
23 P. Roach, T. Parker, N. Gadegaard and M. R. Alexander, Surf.
Sci. Rep., 2010, 65, 145.
24 S. V. Patwardhan, Chem. Commun., 2011, 47, 7567–7582.
25 D. E. Morse, Trends Biotechnol., 1999, 17, 230–232.
26 P. J. Lopez, C. Gautier, J. Livage and T. Coradin, Curr.
Nanosci., 2005, 1, 73–83.
27 M. Hildebrand, Chem. Rev., 2008, 108, 4855–4874.
28 S. V. Patwardhan, S. J. Clarson and C. C. Perry, Chem.
Commun., 2005, 1113–1121.
29 D. J. Belton, S. V. Patwardhan, V. V. Annenkov,
E. N. Danilovtseva and C. C. Perry, Proc. Natl. Acad. Sci. U.
S. A., 2008, 105, 5963–5968.
30 D. J. Belton, S. V. Patwardhan and C. C. Perry, J. Mater.
Chem., 2005, 15, 4629–4638.
31 S. V. Patwardhan and C. C. Perry, Silicon, 2010, 2, 33–39.
32 M. R. Knecht and D. W. Wright, Chem. Mater., 2004, 16,
4890–4895.
33 L. Betancor and H. R. Luckari, Trends Biotechnol., 2008, 26,
566–572.
34 C. Forsyth and S. V. Patwardhan, J. Mater. Chem. B, 2013, 1,
1164–1174.
35 C. Forsyth, T. W. S. Yip and S. V. Patwardhan, Chem.
Commun., 2013, 49, 3191–3193.
36 R. H. Jin and J. J. Yuan, Chem. Mater., 2006, 18, 3390–3396.
This journal is © The Royal Society of Chemistry 2014 J. Mater. Chem. B, 2014, 2, 5028–5042 | 5041
Paper Journal of Materials Chemistry B
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
7 
Ju
ne
 2
01
4.
 D
ow
nl
oa
de
d 
on
 0
5/
08
/2
01
4 
15
:4
4:
08
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
37 R.-H. Jin and J.-J. Yuan, in Advances in Biomimetics, ed. M.
Cavrak, 2011, p. 159.
38 K. I. Sano, T. Minamisawa and K. Shiba, Langmuir, 2010, 26,
2231–2234.
39 K.-I. Sano, T. Minamisawa and K. Shiba, Langmuir, 2010, 26,
2231.
40 C. Forsyth and S. V. Patwardhan, J. Mater. Chem. B, 2013, 1,
1164.
41 A. M. Ewlad-Ahmed, M. A. Morris, S. V. Patwardhan and
L. T. Gibson, Environ. Sci. Technol., 2012, 46, 13354–13360.
42 C. Forsyth, T. W. S. Yip and S. V. Patwardhan, Chem.
Commun., 2013, 49, 3191.
43 A. Vinu, K. Z. Hossain and K. Ariga, J. Nanosci. Nanotechnol.,
2005, 5, 347.
44 Y. L. Huang, B. G. Trewyn, H. T. Chen and V. S. Y. Lin, New J.
Chem., 2008, 32, 1311.
45 S. Shylesh, A. Wagner, A. Seifert, S. Ernst and W. R. Thiel,
Chem.–Eur. J., 2009, 15, 7052.
46 R. Mee, A Comprehensive Guide to Factorial Two-Level
Experimentation, Springer, New York, 2009.
47 G. Decher, Science, 1997, 277, 1232–1237.
48 S. Stoll and P. Chodanowski, Macromolecules, 2002, 35,
9556–9562.
49 D. W. Pack, A. S. Hoﬀman, S. Pun and P. S. Stayton, Nat. Rev.
Drug Discovery, 2005, 4, 581–593.
50 R. de Vries and M. C. Stuart, Curr. Opin. Colloid Interface Sci.,
2006, 11, 295–301.
51 P. L. Ritger and N. A. Peppas, J. Controlled Release, 1987, 5,
23–36.
52 R. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri and
N. A. Peppas, Int. J. Pharm., 1983, 15, 25–35.
53 Y.-f. Zhu, J.-l. Shi, Y.-s. Li, H.-r. Chen, W.-h. Shen and
X.-p. Dong, Microporous Mesoporous Mater., 2005, 85, 75–81.
54 P. L. Ritger and N. A. Peppas, J. Controlled Release, 1987, 5,
37–42.
55 T. Higuchi, J. Pharm. Sci., 1963, 52, 1145–1149.
56 J. C. Doadrio, E. M. B. Sousa, I. Izquierdo-Barba,
A. L. Doadrio, J. Perez-Pariente and M. Vallet-Regi, J. Mater.
Chem., 2006, 16, 462–466.
57 A. L. Doadrio, E. M. B. Sousa, J. C. Doadrio, J. Pe´rez Pariente,
I. Izquierdo-Barba and M. Vallet-Reg´ı, J. Controlled Release,
2004, 97, 125–132.
58 S. V. Patwardhan, G. E. Tilburey and C. C. Perry, Langmuir,
2011, 27, 15135–15145.
59 S. R. Lewis, S. Datta, M. Gui, E. L. Coker, F. E. Huggins,
S. Daunert, L. Bachas and D. Bhattacharyya, Proc. Natl.
Acad. Sci. U. S. A., 2011, 108, 8577–8582.
60 R. W. Sabnis, Handbook of Acid-Base Indicators, CRC Press,
Florida, 2008.
61 C. Lad, N. H. Williams and R. Wolfenden, Proc. Natl. Acad.
Sci. U. S. A., 2003, 100, 5607–5610.
62 R. K. Iler, The chemistry of silica: Solubility, polymerization,
colloid and surface properties and biochemistry, Wiley, New
York, 1979.
63 C. Knox, V. Law, T. Jewison, P. Liu, S. Ly, A. Frolkis, A. Pon,
K. Banco, C. Mak, V. Neveu, Y. Djoumbou, R. Eisner,
A. C. Guo and D. S. Wishart, Nucleic Acids Res., 2011, 39,
D1035–D1041.
64 W. H. De Jong and P. J. A. Borm, Int. J. Nanomed., 2008, 3,
133.
65 D. Napierska, L. C. J. Thomassen, V. Rabolli, D. Lison,
L. Gonzalez, M. Kirsch-Volders, J. A. Martens and
P. H. Hoet, Small, 2009, 5, 846.
66 J.-S. Chang, K. L. B. Chang, D.-F. Hwang and Z.-L. Kong,
Environ. Sci. Technol., 2007, 41, 2064.
67 T. Yu, A. Malugin and H. Ghandehari, ACS Nano, 2011, 5,
5717.
68 N. J. Hallab and J. J. Jacobs, Bull. NYU Hosp. Jt. Dis., 2009, 67,
182.
69 M. Lucarelli, A. M. Gatti, G. Savarino, P. Quattroni,
L. Martinelli, E. Monari and D. Boraschi, Eur. Cytokine
Network, 2004, 15, 339.
70 S. V. Patwardhan, F. S. Emami, R. J. Berry, S. E. Jones,
R. R. Naik, O. Deschaume, H. Heinz and C. C. Perry, J. Am.
Chem. Soc., 2012, 134, 6244.
71 G. J. Hickman, A. Rai, D. J. Boocock, R. C. Rees and
C. C. Perry, J. Mater. Chem., 2012, 22, 12141.
72 M. N. V. Ravi Kumar, M. Sameti, S. S. Mohapatra,
X. Kong, R. F. Lockey, U. Bakowsky, G. Lindenblatt,
H. Schmidt and C. M. Lehr, J. Nanosci. Nanotechnol.,
2004, 4, 876.
73 M. Akbar, A. R. Fraser, G. J. Graham, J. M. Brewer and
M. H. Grant, J. R. Soc., Interface, 2012, 9, 2109.
5042 | J. Mater. Chem. B, 2014, 2, 5028–5042 This journal is © The Royal Society of Chemistry 2014
Journal of Materials Chemistry B Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
7 
Ju
ne
 2
01
4.
 D
ow
nl
oa
de
d 
on
 0
5/
08
/2
01
4 
15
:4
4:
08
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
